ブデソニド吸入器の世界市場レポート 2025年

ブデソニド吸入器の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で96億8,000万米ドルに成長します。予測期間の成長は、呼吸器治療薬開発への投資の増加、呼吸器ケアにおける個別化医療への需要の高まり、遠隔医療と電子処方の利用の拡大、早期診断と治療への意識の高まり、吸入器併用療法への嗜好の高まりに起因すると考えられます。この期間の主な動向には、ドラッグデリバリーを改善するための高度な製剤技術、デジタルトラッキングを備えたスマート吸入器の革新、呼吸器健康管理におけるAIとIoTの統合、患者中心の薬剤設計の進歩、アドヒアランスモニタリングのためのモバイルアプリの組み込みなどがあります。

呼吸器疾患の罹患率の増加は、今後数年間のブデソニド吸入器市場の拡大を促進すると予想されます。肺や気道に影響を及ぼす呼吸器疾患は、呼吸を困難にし、しばしば咳、喘鳴、息切れなどの症状を引き起こします。これらの疾患には、喘息、慢性閉塞性肺疾患（COPD）、肺炎、気管支炎、肺感染症などが含まれます。呼吸器疾患の増加は、気道に刺激を与え肺機能を悪化させる有害な汚染物質に個人をさらす大気汚染の増加に大きく起因しています。ブデソニド吸入薬は、抗炎症薬を肺に直接投与することで、これらの疾患を長期的に管理するのに役立ちます。そのコンパクトなデザインは、使いやすさと携帯性を保証し、再発を予防し、呼吸器の健康を改善します。例えば、オーストラリア統計局によると、オーストラリアにおける慢性閉塞性肺疾患（COPD）の有病率は、2021年の2.4％から2022年には2.5％に増加しました。その結果、呼吸器疾患の有病率の増加がブデソニド吸入器市場の成長に寄与しています。

ブデソニド吸入器市場の主要企業は、手頃な価格で呼吸器疾患の治療を受けられるようにするため、ジェネリック医薬品などの革新的な製品の開発にますます力を入れています。ジェネリック吸入薬は、ブランド品と同じ有効成分、投与量、治療効果を含む非ブランド品の代替品ですが、より低価格です。例えば、2023年7月、Viatris Inc.はKindeva Drug Delivery L.P.との提携により、FDAが承認した最初のシムビコートのジェネリック医薬品であるBreyna（ブデソニド・フマル酸フォルモテロール二水和物）吸入用エアロゾルを発売しました。この薬剤とデバイスの組み合わせは、ブデソニドで気道の炎症を抑え、フォルモテロールで気道周囲の筋肉を弛緩させることで喘息やCOPDを治療するよう設計されており、患者にとってより手頃な選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のブデソニド吸入器のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のブデソニド吸入器市場：成長率分析
• 世界のブデソニド吸入器市場の実績：規模と成長、2019～2024年
• 世界のブデソニド吸入器市場の予測：規模と成長、2024～2029年、2034年
• 世界のブデソニド吸入器総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のブデソニド吸入器市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 定量噴霧式吸入器（MDI）
• ドライパウダー吸入器（DPI）
• ネブライザー
• 配合吸入器
• 世界のブデソニド吸入器市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• エアロゾル
• ドライパウダー
• サスペンション
• スプレー
• 世界のブデソニド吸入器市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 喘息
• 慢性閉塞性肺疾患
• アレルギー性鼻炎
• 世界のブデソニド吸入器市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 外来診療所
• 在宅ケア設定
• 薬局
• 世界のブデソニド吸入器市場：定量噴霧式吸入器のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 加圧式定量噴霧式吸入器
• 呼吸作動式定量噴霧式吸入器
• スペーサー対応定量噴霧式吸入器
• ハイドロフルオロアルカン噴射剤型定量噴霧式吸入器
• 世界のブデソニド吸入器市場：ドライパウダー吸入器のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 単回投与ドライパウダー吸入器
• 多回投与ドライパウダー吸入器
• カプセル型ドライパウダー吸入器
• リザーバー型ドライパウダー吸入器
• 世界のブデソニド吸入器市場：ネブライザーのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジェットネブライザー
• 超音波ネブライザー
• メッシュネブライザー
• ホームケア用ネブライザー
• 病院用ネブライザー
• 世界のブデソニド吸入器市場：配合吸入器のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ブデソニド、フォルモテロール配合吸入器
• ブデソニド、サルメテロール配合吸入器
• ブデソニド、グリコピロレート、フォルモテロール配合吸入器
• ブデソニド、ビランテロール配合吸入器

第7章 地域別・国別分析

• 世界のブデソニド吸入器市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のブデソニド吸入器市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ブデソニド吸入器市場：競合情勢
• ブデソニド吸入器市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Sandoz International GmbH
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Synmosa Biopharma Corporation
• Chiesi Farmaceutici S.p.A.
• Aurobindo Pharma Limited
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Orion Corporation
• Nephron Pharmaceuticals Corporation
• Curia Global Inc.
• Kindeva Drug Delivery L.P.
• Minakem SAS

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ブデソニド吸入器市場2029年：新たな機会を提供する国
• ブデソニド吸入器市場2029年：新たな機会を提供するセグメント
• ブデソニド吸入器市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The budesonide inhaler is a respiratory device that delivers the corticosteroid medication budesonide directly to the lungs. It helps reduce airway inflammation, making breathing easier. The budesonide inhaler is typically prescribed for the long-term management of respiratory diseases.

The main types of products in the budesonide inhaler market include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and combination inhalers. Metered-dose inhalers (MDIs) are handheld medical devices that deliver a precise amount of medication directly to the lungs in the form of a short burst of aerosolized medicine. The available dosage forms include aerosols, dry powder, suspension, and spray, each indicated for different conditions such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The primary end-users of these products include hospitals, outpatient clinics, home care settings, and pharmacies.

The budesonide inhaler market research report is one of a series of new reports from The Business Research Company that provides budesonide inhaler market statistics, including budesonide inhaler industry global market size, regional shares, competitors with a budesonide inhaler market share, detailed budesonide inhaler market segments, market trends and opportunities, and any further data you may need to thrive in the budesonide inhaler industry. This budesonide inhaler market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The budesonide inhaler market size has grown strongly in recent years. It will grow from $6.37 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to heightened awareness of inhalation therapies, growing adoption of corticosteroid treatments, rising air pollution levels leading to respiratory problems, increasing demand for minimally invasive drug delivery methods, and a stronger focus on home healthcare solutions.

The budesonide inhaler market size is expected to see strong growth in the next few years. It will grow to $9.68 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in respiratory drug development, rising demand for personalized medicine in respiratory care, greater use of telemedicine and e-prescriptions, heightened awareness of early diagnosis and treatment, and a growing preference for combination inhaler therapies. Key trends during this period include advanced formulation techniques for improved drug delivery, innovations in smart inhalers with digital tracking, the integration of AI and IoT in respiratory health management, advancements in patient-centric drug designs, and the incorporation of mobile apps for adherence monitoring.

The growing incidence of respiratory disorders is expected to drive the expansion of the budesonide inhaler market in the coming years. Respiratory disorders, which affect the lungs and airways, can make breathing difficult and often lead to symptoms such as coughing, wheezing, and shortness of breath. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung infections. The rise in respiratory disorders is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and worsen lung function. Budesonide inhalers help manage these disorders by delivering anti-inflammatory medication directly to the lungs, providing long-term control. Their compact design ensures ease of use and portability, reducing flare-ups and improving respiratory health. For example, according to the Australian Bureau of Statistics, the prevalence of chronic obstructive pulmonary disease (COPD) in Australia increased from 2.4% in 2021 to 2.5% in 2022. As a result, the growing prevalence of respiratory disorders is fueling the growth of the budesonide inhaler market.

Leading companies in the budesonide inhaler market are increasingly focused on developing innovative products, such as generic versions, to enhance affordability and broaden access to treatment for respiratory conditions. Generic inhalers are non-branded alternatives that contain the same active ingredients, dosage, and therapeutic effects as their branded counterparts, but typically at a lower price. For example, in July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery L.P., launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of Symbicort. This drug-device combination is designed to treat asthma and COPD by reducing airway inflammation with budesonide, while formoterol relaxes the muscles around the airways, offering a more affordable option for patients.

In January 2025, Molex, a US-based electronics company, acquired Vectura Group Ltd. for an undisclosed sum. Through this acquisition, Molex aims to establish a leading position in inhalation drug delivery by combining Phillips Medisize's manufacturing expertise with Vectura's specialization in inhalation devices and formulation development. This move will enhance Molex's ability to deliver innovative therapies for respiratory conditions. Vectura Group, based in the UK, is known for its work in developing inhalation drug delivery systems, including those used to administer budesonide.

Major players in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

North America was the largest region in the budesonide inhaler market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in budesonide inhaler report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the budesonide inhaler market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The budesonide inhaler market consists of sales of soft mist inhalers, nasal inhalers, budesonide repulse, oral inhalation capsules, and transdermal inhalation systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Budesonide Inhaler Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on budesonide inhaler market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for budesonide inhaler ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The budesonide inhaler market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers; Combination Inhalers
• 2) By Dosage Form: Aerosols; Dry Powder; Suspension; Spray
• 3) By Indication: Asthma; Chronic Obstructive Pulmonary Disease; Allergic Rhinitis
• 4) By End User: Hospitals; Outpatient Clinics; Homecare Settings; Pharmacies
• Subsegments:
• 1) Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers; Breath-Actuated Metered-Dose Inhalers; Spacer-Compatible Metered-Dose Inhalers; Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers
• 2) Dry Powder Inhalers: Single-Dose Dry Powder Inhalers; Multi-Dose Dry Powder Inhalers; Capsule-Based Dry Powder Inhalers; Reservoir-Based Dry Powder Inhalers
• 3) Nebulizers: Jet Nebulizers; Ultrasonic Nebulizers; Mesh Nebulizers; Homecare Nebulizers; Hospital-Use Nebulizers
• 4) Combination Inhalers: Budesonide And Formoterol Inhalers; Budesonide And Salmeterol Inhalers; Budesonide, Glycopyrrolate, And Formoterol Inhalers; Budesonide And Vilanterol Inhalers
• Companies Mentioned: AstraZeneca plc; GSK plc; Takeda Pharmaceutical Company Limited; Viatris Inc.; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Budesonide Inhaler Market Characteristics

3. Budesonide Inhaler Market Trends And Strategies

4. Budesonide Inhaler Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Budesonide Inhaler Growth Analysis And Strategic Analysis Framework

• 5.1. Global Budesonide Inhaler PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Budesonide Inhaler Market Growth Rate Analysis
• 5.4. Global Budesonide Inhaler Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Budesonide Inhaler Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Budesonide Inhaler Total Addressable Market (TAM)

6. Budesonide Inhaler Market Segmentation

• 6.1. Global Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metered-Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Nebulizers
• Combination Inhalers
• 6.2. Global Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aerosols
• Dry Powder
• Suspension
• Spray
• 6.3. Global Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Obstructive Pulmonary Disease
• Allergic Rhinitis
• 6.4. Global Budesonide Inhaler Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Outpatient Clinics
• Homecare Settings
• Pharmacies
• 6.5. Global Budesonide Inhaler Market, Sub-Segmentation Of Metered-Dose Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pressurized Metered-Dose Inhalers
• Breath-Actuated Metered-Dose Inhalers
• Spacer-Compatible Metered-Dose Inhalers
• Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers
• 6.6. Global Budesonide Inhaler Market, Sub-Segmentation Of Dry Powder Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Dry Powder Inhalers
• Multi-Dose Dry Powder Inhalers
• Capsule-Based Dry Powder Inhalers
• Reservoir-Based Dry Powder Inhalers
• 6.7. Global Budesonide Inhaler Market, Sub-Segmentation Of Nebulizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Jet Nebulizers
• Ultrasonic Nebulizers
• Mesh Nebulizers
• Homecare Nebulizers
• Hospital-Use Nebulizers
• 6.8. Global Budesonide Inhaler Market, Sub-Segmentation Of Combination Inhalers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Budesonide And Formoterol Inhalers
• Budesonide And Salmeterol Inhalers
• Budesonide, Glycopyrrolate, And Formoterol Inhalers
• Budesonide And Vilanterol Inhalers

7. Budesonide Inhaler Market Regional And Country Analysis

• 7.1. Global Budesonide Inhaler Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Budesonide Inhaler Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Budesonide Inhaler Market

• 8.1. Asia-Pacific Budesonide Inhaler Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Budesonide Inhaler Market

• 9.1. China Budesonide Inhaler Market Overview
• 9.2. China Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Budesonide Inhaler Market

• 10.1. India Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Budesonide Inhaler Market

• 11.1. Japan Budesonide Inhaler Market Overview
• 11.2. Japan Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Budesonide Inhaler Market

• 12.1. Australia Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Budesonide Inhaler Market

• 13.1. Indonesia Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Budesonide Inhaler Market

• 14.1. South Korea Budesonide Inhaler Market Overview
• 14.2. South Korea Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Budesonide Inhaler Market

• 15.1. Western Europe Budesonide Inhaler Market Overview
• 15.2. Western Europe Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Budesonide Inhaler Market

• 16.1. UK Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Budesonide Inhaler Market

• 17.1. Germany Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Budesonide Inhaler Market

• 18.1. France Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Budesonide Inhaler Market

• 19.1. Italy Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Budesonide Inhaler Market

• 20.1. Spain Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Budesonide Inhaler Market

• 21.1. Eastern Europe Budesonide Inhaler Market Overview
• 21.2. Eastern Europe Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Budesonide Inhaler Market

• 22.1. Russia Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Budesonide Inhaler Market

• 23.1. North America Budesonide Inhaler Market Overview
• 23.2. North America Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Budesonide Inhaler Market

• 24.1. USA Budesonide Inhaler Market Overview
• 24.2. USA Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Budesonide Inhaler Market

• 25.1. Canada Budesonide Inhaler Market Overview
• 25.2. Canada Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Budesonide Inhaler Market

• 26.1. South America Budesonide Inhaler Market Overview
• 26.2. South America Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Budesonide Inhaler Market

• 27.1. Brazil Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Budesonide Inhaler Market

• 28.1. Middle East Budesonide Inhaler Market Overview
• 28.2. Middle East Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Budesonide Inhaler Market

• 29.1. Africa Budesonide Inhaler Market Overview
• 29.2. Africa Budesonide Inhaler Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Budesonide Inhaler Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Budesonide Inhaler Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Budesonide Inhaler Market Competitive Landscape And Company Profiles

• 30.1. Budesonide Inhaler Market Competitive Landscape
• 30.2. Budesonide Inhaler Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Budesonide Inhaler Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Sandoz International GmbH
• 31.3. Bausch Health Companies Inc.
• 31.4. Sun Pharmaceutical Industries Ltd.
• 31.5. Synmosa Biopharma Corporation
• 31.6. Chiesi Farmaceutici S.p.A.
• 31.7. Aurobindo Pharma Limited
• 31.8. Cipla Limited
• 31.9. Hikma Pharmaceuticals PLC
• 31.10. Lupin Limited
• 31.11. Orion Corporation
• 31.12. Nephron Pharmaceuticals Corporation
• 31.13. Curia Global Inc.
• 31.14. Kindeva Drug Delivery L.P.
• 31.15. Minakem SAS

32. Global Budesonide Inhaler Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Budesonide Inhaler Market

34. Recent Developments In The Budesonide Inhaler Market

35. Budesonide Inhaler Market High Potential Countries, Segments and Strategies

• 35.1 Budesonide Inhaler Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Budesonide Inhaler Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Budesonide Inhaler Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer